Developer docs
API playgroundTry for free, no card

Search company profiles

RxMP Therapeutics

Full company profile

uuid0003g7f

Namestring
RxMP Therapeutics
Legal namestring
RxMP Therapeutics, Inc.
Websiteurl
rxmpt.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

RxMP Therapeutics is a privately held, late pre-clinical stage biopharmaceutical company developing a first-in-class hemostatic therapeutic, RMP-402, based on its proprietary red cell-derived microparticle (RMP) platform. RMPs are allogeneic red blood cell membrane particles manufactured via high-pressure extrusion of human packed red blood cells; RMP-402 is designed to be administered intravenously to rapidly arrest or prevent severe bleeding by enhancing both primary hemostasis (platelet function) and secondary hemostasis (coagulation) without increasing the risk of off-target clotting. The company is pursuing both civilian healthcare applications (trauma centers, hospitals, surgical settings) and military/combat-casualty-care applications, and is in active discussions with the U.S. Department of Defense on a potential Emergency Use Authorization pathway.

The company's go-to-market model centers on enterprise field sales to hospitals, trauma centers, and military medical channels upon regulatory approval, with a one-time license/product-sale revenue model. To date, RxMP has no commercialized product and is pre-revenue; it has been funded primarily by approximately $11 million in grants and $5.5 million in equity investment, anchored by the Wallace H. Coulter Foundation as its largest shareholder, and opened a $2 million bridge financing round in December 2025. Strategic infrastructure includes an FDA consensus on its cGMP manufacturing process achieved in 2025, a CRADA with the DoD's Institute of Surgical Research for preclinical validation, and an April 2026 contract manufacturing partnership with OrganaBio for cGMP production. The company is led by founder/CEO Rifat Pamukcu and CSO Wenche Jy, both with multi-decade expertise in the underlying science.

Revenue economics remain entirely contingent on future regulatory approval and commercialization of RMP-402; the company is headquartered in Rancho Santa Fe, California, operates with 1–10 employees, and targets a global trauma and surgical bleeding market estimated at $12 billion annually.

Short descriptiontext

RxMP Therapeutics is a late pre-clinical biopharmaceutical company developing RMP-402, a first-in-class intravenous hemostatic therapeutic based on proprietary red cell-derived microparticles, targeting severe bleeding in civilian trauma and military combat-casualty-care settings.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hemostatic therapeutics, hemorrhage control drugs, red blood cell microparticles, pharmaceutical drug development, trauma bleeding treatment
Industry5 codes
PRIMARYHLAMAEAA
Companion Animal Therapeutics (Rx)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAMANAB
Platelet-Rich Plasma (PRP) & Blood-Derived Orthobiologics
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLACANAO
DTx/SaMD Deployment, Integration & Reimbursement Enablement
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAA
Condition-specific Digital Therapeutics (DTx)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Hemostatic Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue company. Future revenue expected from sale of RMP-402 hemostatic therapeutic product for severe hemorrhage control in civilian and military settings upon regulatory approval.

rxmpt.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

RxMP Therapeutics is developing RMP-402, a first-in-class hemostatic therapeutic composed of manufactured allogeneic red cell membrane particles (RMPs) designed to be administered intravenously to rapidly arrest or prevent severe bleeding without increasing the risk of off-target clotting. RMP-402 is being developed for severe hemorrhage control in civilian trauma centers and hospitals as well as for military combat casualty care, with a global trauma and surgical bleeding market estimated at $12 billion annually.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Demonstrated efficacy in multiple animal models of bleeding and hemorrhage across species with high level of safety
+1 more record
Product overview1 text field

RxMP Therapeutics is developing a novel hemostatic platform based on red cell-derived microparticles (RMPs). The company's lead product candidate, RMP-402, is a first-in-class hemostatic therapeutic composed of manufactured allogeneic red cell membrane particles designed to arrest or prevent excessive bleeding systemically. The technology is based on naturally occurring RMPs that support coagulation by serving as sites for the assembly of clotting factors and enhancing platelet function.

Product and service1 record
1RMP-402 Hemostatic Therapeutic
CategoryHemostatic Pharmaceuticals
Description

RMP-402 is a first-in-class hemostatic therapeutic composed of manufactured allogeneic red cell membrane particles (RMPs) — analogs of particles that circulate naturally in human blood. It is administered intravenously and is designed to rapidly stop severe bleeding without increasing the risk of off-target clotting, enhancing both primary hemostasis (platelet function) and secondary hemostasis (coagulation). It is being developed for both civilian healthcare (trauma centers, hospitals, surgical facilities) and military combat casualty care settings.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

OrganaBio serves as RxMP's contract manufacturing partner for cGMP production of RMP-402. The agreement covers technology transfer, qualification, and cGMP production leveraging OrganaBio's integrated manufacturing infrastructure and quality management systems. This is a critical partnership for advancing the drug product through key development milestones toward regulatory approval.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-01
Description

RxMP entered into a Cooperative Research and Development Agreement (CRADA) with the Institute of Surgical Research, a subordinate federal laboratory of the Defense Health Agency within the DoD. Under the CRADA, RxMP provides RMP-402 and red cell-derived lyophilized microparticles to ISR for validation studies promoting coagulation function in large animal preclinical models of polytrauma hemorrhage and shock.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

CSL Behring markets a broad portfolio of plasma-derived and recombinant coagulation products for hemophilia and surgical bleeding, overlapping with RxMP's target indications and representing a likely strategic acquirer in the hemostatic space.

TypeBroad incumbent
Description

Octapharma is a major global plasma products manufacturer with a portfolio of coagulation factor concentrates and hemostatic therapies serving trauma, surgery and bleeding disorders, making it a broad incumbent competitor and potential strategic acquirer of RxMP.

TypeBroad incumbent
Description

Grifols produces plasma-derived coagulation factors and other hemostatic products for hospital and trauma use, directly overlapping with RxMP's civilian hospital/trauma-center target market and a credible strategic acquirer.

TypeEmerging player
Description

Cerus develops pathogen-reduced blood components and INTERCEPT-treated platelets and plasma used in transfusion and bleeding management, sharing the blood-component-based therapeutic approach with RxMP's red cell-derived platform.

TypeBroad incumbent
Description

Takeda's rare bleeding disorder and hemophilia franchise (formerly Baxalta/Shire) competes in the same hospital and specialty hemostasis segments RxMP targets and serves as a benchmark strategic acquirer for late-stage hemostatic assets.

TypeDirect peer
Description

Cellphire is developing thrombosomes, a lyophilized platelet-derived hemostatic product for severe bleeding, the closest mechanistic analog to RxMP's red cell-derived microparticle approach and the most directly comparable hemostatic therapeutic peer.

TypeDirect peer
Description

Haima is developing synthetic platelet-like particles for hemorrhage control, directly comparable to RxMP's synthetic red cell-derived microparticle platform in mechanism (mimicking natural hemostatic particles) and target indications (trauma, surgical bleeding).

TypeEmerging player
Description

Velico is developing spray-dried plasma and other blood-derived emergency hemostatic products for trauma use, a directly comparable early-stage approach to providing off-the-shelf hemostatic therapy in military and civilian settings.

9Medicines Company / CSL Seqirus (tranexamic acid)
TypeBroad incumbent
Description

The originator of intravenous tranexamic acid (TXA), currently the standard-of-care systemic hemostatic for trauma, represents RxMP's principal clinical comparator and incumbent in the trauma hemostasis market RxMP is targeting.

TypeEmerging player
Description

RevMedX develops advanced hemostatic devices (e.g., XSTAT, XGAUZE) used by the U.S. military and EMS for severe hemorrhage control, sharing RxMP's military and civilian trauma-channel focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RxMP Therapeutics

Hemostatic Pharmaceuticalsrxmpt.com

RxMP Therapeutics is a late pre-clinical biopharmaceutical company developing RMP-402, a first-in-class intravenous hemostatic therapeutic based on proprietary red cell-derived microparticles, targeting severe bleeding in civilian trauma and military combat-casualty-care settings.

What RxMP Therapeutics does

RxMP Therapeutics is a privately held, late pre-clinical stage biopharmaceutical company developing a first-in-class hemostatic therapeutic, RMP-402, based on its proprietary red cell-derived microparticle (RMP) platform. RMPs are allogeneic red blood cell membrane particles manufactured via high-pressure extrusion of human packed red blood cells; RMP-402 is designed to be administered intravenously to rapidly arrest or prevent severe bleeding by enhancing both primary hemostasis (platelet function) and secondary hemostasis (coagulation) without increasing the risk of off-target clotting. The company is pursuing both civilian healthcare applications (trauma centers, hospitals, surgical settings) and military/combat-casualty-care applications, and is in active discussions with the U.S. Department of Defense on a potential Emergency Use Authorization pathway.

The company's go-to-market model centers on enterprise field sales to hospitals, trauma centers, and military medical channels upon regulatory approval, with a one-time license/product-sale revenue model. To date, RxMP has no commercialized product and is pre-revenue; it has been funded primarily by approximately $11 million in grants and $5.5 million in equity investment, anchored by the Wallace H. Coulter Foundation as its largest shareholder, and opened a $2 million bridge financing round in December 2025. Strategic infrastructure includes an FDA consensus on its cGMP manufacturing process achieved in 2025, a CRADA with the DoD's Institute of Surgical Research for preclinical validation, and an April 2026 contract manufacturing partnership with OrganaBio for cGMP production. The company is led by founder/CEO Rifat Pamukcu and CSO Wenche Jy, both with multi-decade expertise in the underlying science.

Revenue economics remain entirely contingent on future regulatory approval and commercialization of RMP-402; the company is headquartered in Rancho Santa Fe, California, operates with 1–10 employees, and targets a global trauma and surgical bleeding market estimated at $12 billion annually.

RxMP Therapeutics firmographics

Firmographics
Name
RxMP Therapeutics
Legal name
RxMP Therapeutics, Inc.
Website
https://rxmpt.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
RxMP Therapeutics is a late pre-clinical biopharmaceutical company developing RMP-402, a first-in-class intravenous hemostatic therapeutic based on proprietary red cell-derived microparticles, targeting severe bleeding in civilian trauma and military combat-casualty-care settings.
Ownership category
akta.pro rank

RxMP Therapeutics industry classification

Industry
Product category
Hemostatic Pharmaceuticals
NAICS
Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAMAEAA
Companion Animal Therapeutics (Rx)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAMANAB
Platelet-Rich Plasma (PRP) & Blood-Derived Orthobiologics
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLACANAO
DTx/SaMD Deployment, Integration & Reimbursement Enablement
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAA
Condition-specific Digital Therapeutics (DTx)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Hemostatic therapeutics
  • Hemorrhage control drugs
  • Red blood cell microparticles
  • Pharmaceutical drug development
  • Trauma bleeding treatment

Where RxMP Therapeutics is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices1 record

Markets served

RxMP Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue company. Future revenue expected from sale of RMP-402 hemostatic therapeutic product for severe hemorrhage control in civilian and military settings upon regulatory approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

RxMP Therapeutics product offering

Product offering

Core offering

RxMP Therapeutics is developing RMP-402, a first-in-class hemostatic therapeutic composed of manufactured allogeneic red cell membrane particles (RMPs) designed to be administered intravenously to rapidly arrest or prevent severe bleeding without increasing the risk of off-target clotting. RMP-402 is being developed for severe hemorrhage control in civilian trauma centers and hospitals as well as for military combat casualty care, with a global trauma and surgical bleeding market estimated at $12 billion annually.

Product overview

RxMP Therapeutics is developing a novel hemostatic platform based on red cell-derived microparticles (RMPs). The company's lead product candidate, RMP-402, is a first-in-class hemostatic therapeutic composed of manufactured allogeneic red cell membrane particles designed to arrest or prevent excessive bleeding systemically. The technology is based on naturally occurring RMPs that support coagulation by serving as sites for the assembly of clotting factors and enhancing platelet function.

Differentiator

Problem solved

Functional benefit

Products and services

  • RMP-402 Hemostatic Therapeutic RMP-402 is a first-in-class hemostatic therapeutic composed of manufactured allogeneic red cell membrane particles (RMPs) — analogs of particles that circulate naturally in human blood. It is administered intravenously and is designed to rapidly stop severe bleeding without increasing the risk of off-target clotting, enhancing both primary hemostasis (platelet function) and secondary hemostasis (coagulation). It is being developed for both civilian healthcare (trauma centers, hospitals, surgical facilities) and military combat casualty care settings.

Quantifiable outcome

  • Demonstrated efficacy in multiple animal models of bleeding and hemorrhage across species with high level of safety
  • +1 more outcomes

Companies that use RxMP Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

RxMP Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

RxMP Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • OrganaBiocoreStrategic or Co-development Partner · 22 April 2026OrganaBio serves as RxMP's contract manufacturing partner for cGMP production of RMP-402. The agreement covers technology transfer, qualification, and cGMP production leveraging OrganaBio's integrated manufacturing infrastructure and quality management systems. This is a critical partnership for advancing the drug product through key development milestones toward regulatory approval.
  • U.S. Department of Defense Institute of Surgical ResearchcoreStrategic or Co-development Partner · 1 March 2025RxMP entered into a Cooperative Research and Development Agreement (CRADA) with the Institute of Surgical Research, a subordinate federal laboratory of the Defense Health Agency within the DoD. Under the CRADA, RxMP provides RMP-402 and red cell-derived lyophilized microparticles to ISR for validation studies promoting coagulation function in large animal preclinical models of polytrauma hemorrhage and shock.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

RxMP Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • CSL Behring: CSL Behring markets a broad portfolio of plasma-derived and recombinant coagulation products for hemophilia and surgical bleeding, overlapping with RxMP's target indications and representing a likely strategic acquirer in the hemostatic space.
  • Octapharma: Octapharma is a major global plasma products manufacturer with a portfolio of coagulation factor concentrates and hemostatic therapies serving trauma, surgery and bleeding disorders, making it a broad incumbent competitor and potential strategic acquirer of RxMP.
  • Grifols: Grifols produces plasma-derived coagulation factors and other hemostatic products for hospital and trauma use, directly overlapping with RxMP's civilian hospital/trauma-center target market and a credible strategic acquirer.
  • Takeda Pharmaceutical: Takeda's rare bleeding disorder and hemophilia franchise (formerly Baxalta/Shire) competes in the same hospital and specialty hemostasis segments RxMP targets and serves as a benchmark strategic acquirer for late-stage hemostatic assets.
  • Medicines Company / CSL Seqirus (tranexamic acid): The originator of intravenous tranexamic acid (TXA), currently the standard-of-care systemic hemostatic for trauma, represents RxMP's principal clinical comparator and incumbent in the trauma hemostasis market RxMP is targeting.

Emerging players

  • Cerus Corporation: Cerus develops pathogen-reduced blood components and INTERCEPT-treated platelets and plasma used in transfusion and bleeding management, sharing the blood-component-based therapeutic approach with RxMP's red cell-derived platform.
  • Velico Medical: Velico is developing spray-dried plasma and other blood-derived emergency hemostatic products for trauma use, a directly comparable early-stage approach to providing off-the-shelf hemostatic therapy in military and civilian settings.
  • RevMedX: RevMedX develops advanced hemostatic devices (e.g., XSTAT, XGAUZE) used by the U.S. military and EMS for severe hemorrhage control, sharing RxMP's military and civilian trauma-channel focus.

Direct peers

  • Cellphire Therapeutics: Cellphire is developing thrombosomes, a lyophilized platelet-derived hemostatic product for severe bleeding, the closest mechanistic analog to RxMP's red cell-derived microparticle approach and the most directly comparable hemostatic therapeutic peer.
  • Haima Therapeutics: Haima is developing synthetic platelet-like particles for hemorrhage control, directly comparable to RxMP's synthetic red cell-derived microparticle platform in mechanism (mimicking natural hemostatic particles) and target indications (trauma, surgical bleeding).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights7 records

Customer concentration

RxMP Therapeutics social profiles

Digital presence

RxMP Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RxMP Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

RxMP Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RxMP Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RxMP Therapeutics

What does RxMP Therapeutics do?

RxMP Therapeutics is developing RMP-402, a first-in-class hemostatic therapeutic composed of manufactured allogeneic red cell membrane particles (RMPs) designed to be administered intravenously to rapidly arrest or prevent severe bleeding without increasing the risk of off-target clotting. RMP-402 is being developed for severe hemorrhage control in civilian trauma centers and hospitals as well as for military combat casualty care, with a global trauma and surgical bleeding market estimated at $12 billion annually.

Is RxMP Therapeutics a public or private company?

RxMP Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was RxMP Therapeutics founded?

RxMP Therapeutics was founded in 2013. It employs 1 to 10 people.

Where is RxMP Therapeutics based?

RxMP Therapeutics is headquartered in Seattle, United States, in the North America region.

How does RxMP Therapeutics make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are RxMP Therapeutics's main competitors?

Broad incumbents on record are CSL Behring, Octapharma, Grifols, Takeda Pharmaceutical and Medicines Company / CSL Seqirus (tranexamic acid). Emerging players are Cerus Corporation, Velico Medical and RevMedX. Direct peers are Cellphire Therapeutics and Haima Therapeutics.

Does RxMP Therapeutics have an API?

No public API is recorded for RxMP Therapeutics.

What industry is RxMP Therapeutics in?

RxMP Therapeutics's product category is Hemostatic Pharmaceuticals. Its primary akta.pro industry code is HLAMAEAA, Companion Animal Therapeutics (Rx), with a secondary code of HLACANAM, DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms. Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireDARPA Awards up to $10.7 Million Contract to RxMP Therapeutics, Inc.DARPA awarded RxMP Therapeutics up to $10.7 million under its RAPIID program to advance RMP-402, a hemostatic biomimetic. The funding will support IND-enabling development, manufacturing scale-up, and IND application preparation. The company aims to enter clinical trials and potentially seek Emergency Use Authorization.BioSpaceOrganaBio and RxMP Therapeutics Announce Manufacturing Partnership to Advance RMP-402 Hemostatic Drug ProductOrganaBio and RxMP Therapeutics announced a manufacturing partnership for the cGMP production of RMP-402, a first-in-class hemostatic drug. The partnership aims to advance the drug through development milestones, with RxMP having reached FDA consensus in 2025. RMP-402 targets a global trauma and surgical bleeding market estimated at $12 billion annually.PR NewswireOrganaBio and RxMP Therapeutics Announce Manufacturing Partnership to Advance RMP-402 Hemostatic Drug ProductOrganaBio and RxMP Therapeutics announced a manufacturing partnership on April 22, 2026, under which OrganaBio will serve as RxMP's contract manufacturing partner for cGMP production of its lead product candidate RMP-402, a first-in-class hemostatic therapeutic for severe hemorrhage. The agreement covers technology transfer, qualification, and cGMP production leveraging OrganaBio's integrated manufacturing infrastructure. RMP-402 is being developed for both civilian and military settings targeting a global trauma and surgical bleeding market estimated at $12 billion annually.Business Wire BlogOrganaBio and RxMP Therapeutics Announce Manufacturing Partnership to Advance RMP-402 Hemostatic Drug ProductOrganaBio and RxMP Therapeutics announced a manufacturing partnership for RMP-402, a hemostatic drug, with OrganaBio serving as contract manufacturer. RxMP reached FDA consensus on its GMP process and signed a CRADA with the U.S. Department of Defense. The partnership aims to advance the drug for civilian and military use.